Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results
Sign Up to like & getrecommendations! Published in 2025 at "Blood Advances"
DOI: 10.1182/bloodadvances.2024015493
Abstract: Key Points • Only 40% of intolerance AEs in cohort 1 (ibrutinib intolerance) and 28% in cohort 2 (acalabrutinib intolerance) recurred with zanubrutinib.• After switching to zanubrutinib, 71% of patients in cohort 1 and 63%… read more here.
Keywords: tolerated effective; ibrutinib; effective patients; patients cll ... See more keywords